Dermatology Times: New Research Highlights Zabalafin Hydrogel’s Novel Multitargeted Approach to AD Treatment
by Marie Bosslett
A new paper highlights Alphyn Biologics’ Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195